Literature DB >> 14661546

[Comparison of corneal and conjunctival rose bengal staining before and after punctal occlusion].

Yumi Hirotani1, Norihiko Yokoi, Hirokatsu Tsuzuki, Shigeru Kinoshita.   

Abstract

PURPOSE: In severely tear-deficient dry eye patients whose puncta had been occluded, corneal and conjunctival rose bengal (RB) staining were graded and compared to before occlusion. SUBJECTS AND METHODS: Subjects were 17 eyes of 13 severely tear-deficient dry eye patients whose puncta had been successfully occluded (corneal fluorescein staining showed A 0 D 0 after occlusion). Corneal and conjunctival RB staining were graded 0, 1, 2 or 3, according to severity [B 1] at the cornea and at the temporal and nasal bulbar conjunctiva. The scores were then compared to those before punctal occlusion. To enable comparison of pre- and post-occlusion ocular surface concentrations of RB [B 2], post-occlusion concentration was adjusted by absorbing tears from the conjunctival sac with Schirmer's test paper until the lower meniscus height was equal to that before occlusion, as monitored by video-meniscometer. RB dye was then instilled into the patients conjunctival sac.
RESULTS: RB staining score at the cornea decreased significantly; in contrast, no significant improvement was found at the nasal and temporal conjunctiva (p = 0.0025, p = 0.05, p = 0.7, respectively, Wilcoxon test).
CONCLUSION: In accordance with the basic interpretation of RB staining, these results imply that RB positive staining [B 3] on the conjunctival surface is caused by a factor other than aqueous deficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661546

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  1 in total

1.  Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.

Authors:  N Yokoi; Y Sonomura; H Kato; A Komuro; S Kinoshita
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.